Search
prucalopride (Resotran, Motegrity)
Indications:
- chronic constipation
- refractory Ogilvie's syndrome (colonic pseudo-obstruction) [3]
Contraindications:
- Crohn's disease
- ulcerative colitis
- toxic megacolon/megarectum
Dosage:
- 2 mg PO QD
- 1 mg P QD > 65 years of age
Adverse effects:
- headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, fatigue [2]
- depression, reports of suicidal ideation (monitor)
- uncharacterized (on list of drugs to avoid) [1]
Mechanism of action:
- 5-HT4 receptor agonist
- stimulates colonic peristalsis
General
amide
ether
amine
heterocyclic compound, 2 rings
laxative
Database Correlations
PUBCHEM correlations
References
- Therapeutics Letter #108. Therapeutics Initiative
Drugs to Avoid.
http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
- Brooks M
FDA OKs Prucalopride (Motegrity) for Chronic Idiopathic Constipation.
Medscape - Dec 18, 2018.
https://www.medscape.com/viewarticle/906732
- Musa A, Geimadi A, Georgis MT et al
Ogilvie Syndrome (Acute Colonic Pseudo-obstruction): Early Recognition and
Treatment Are Key.
Medscape. Nov 18, 2022
https://reference.medscape.com/slideshow/ogilvie-syndrome-6014904